Author: Francisca Verdugo-Paiva; Ariel Izcovich; Martin Ragusa; Gabriel Rada
Title: Lopinavir/ritonavir f?or the treatment of COVID-19: A living systematic review protocol Document date: 2020_4_17
ID: mhi6w4mr_42
Snippet: Using standardised forms, two reviewers will extract data independently from each included study. We will collect the following information: study design, setting, participant characteristics (including disease severity and age) and study eligibility criteria; details about the administered intervention and comparison, including dose and therapeutic scheme, duration, timing (i.e. time after diagnosis) and route of administration; the outcomes ass.....
Document: Using standardised forms, two reviewers will extract data independently from each included study. We will collect the following information: study design, setting, participant characteristics (including disease severity and age) and study eligibility criteria; details about the administered intervention and comparison, including dose and therapeutic scheme, duration, timing (i.e. time after diagnosis) and route of administration; the outcomes assessed and the time they were measured; the source of funding of the study and the conflicts of interest disclosed by the investigators; the risk of bias assessment for each individual study.
Search related documents:
Co phrase search for related documents- disease severity and include study: 1, 2, 3, 4, 5, 6, 7
- disease severity and individual study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- disease severity and individual study bias assessment: 1
- disease severity and individual study bias assessment risk: 1
- disease severity and measure time: 1, 2, 3
- disease severity and outcome assess: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- disease severity and standardised form: 1, 2
- disease severity and study design: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- disease severity and study funding: 1, 2, 3, 4, 5, 6, 7, 8, 9
- disease severity and study funding source: 1
- disease severity and therapeutic dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- disease severity and therapeutic dose scheme: 1
- follow information and outcome assess: 1
- follow information and study design: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- follow information and study funding: 1
- study design and therapeutic dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- study design and therapeutic dose scheme: 1
- study funding and therapeutic dose: 1, 2
- study funding and therapeutic dose scheme: 1
Co phrase search for related documents, hyperlinks ordered by date